前列腺素E1对高血压并发糖耐量减低患者血浆P-选择素的影响

Effects of Lipo-prostaglandin E1 on Plasma GMP-140 in Hypertensive Patients with Impaired Glucose Tolerance

目的:观察应用前列腺素E1(PGE1)治疗单纯原发性高血压(HT)、HT并发糖耐量减低(IGT)患者及健康者血浆P-选择素浓度,探讨HT及其危险因素的防治措施。方法:HT患者20例为A组、HT并发IGT患者40例为B组,均采用PGE1注射液静脉滴注。治疗前和治疗7d后次日及健康者(对照组)体检当日测定血浆P-选择素等各项指标。结果:治疗前A、B组患者血浆P-选择素浓度明显高于对照组(P<0.01),B组更显著;治疗后此2组均有下降(P<0.05,0.01),胰岛素抵抗指数(HOMA-IR)较治疗前有不同程度下降;B组餐后2h血糖明显高于对照组和A组。结论:HT患者血浆P-选择素浓度升高,尤其并发IGT患者升高更明显;PGE1能改善HT和并发IGT患者异常血浆P-选择素浓度;HT并发IGT患者血浆P-选择素浓度与年龄、BMI、腰围、臀围、FBG、2HPG、FINS、HOMA-IR、SBP、DBP呈正相关。

Objective：To observe the changes of plasma GMP-140 levels in primary hypertensive patients with normal glucose tolerance, hypertensive patients with impaired glucose tolerance （IGT） treated with Lipo-prostaglandin E1 （PGE1）, and explore the prevention measures of hypertension and risk factors. Methods： Twenty hypertensive patients （group A） and 40 hypertensive patients with IGT （group B） were intravenously injected with PGE1. Before and 7 days after treatment, and at the same time after medical examination of the healthy volunteers （control group）, plasma GMP-140 level was determined. Results： As compared with control group, the level of plasma GMP-140 in group A and group B before treatment was significantly increased （P〈0.01）, more significant in group B. After treatment, the level of GMP 140 in groups A and B was reduced as compared with that before treatment （P〈0.05）, but there was no significant difference between groups A and B. The level of GMP-140 had a positive correlation with age, BMI, waist circumference, FPG, 2HPGFINS, HOMA-IR, SBP and DBP in hypertensive patients with IGT. Conclusion：Plasma GMP-140 levels in patients with primary hypertension was increased, especially in hypertensive patients with IGT. Lipo-PGE1 can increase the levels of abnormal plasma GMP-140. The level of GMP 140 had a positive correlation with age, BMI, waist circum- ference, FPG, 2HPGFINS, HOMA-IR, SBP and DBP in hypertensive patients with IGT.